SOUTHERN BLOTTING MARKET ANALYSIS

Southern Blotting Market Introduction

Molecular biology has gained significant momentum over the last decade with increasing R&D spending on development of therapeutic drugs. It has wide role across various healthcare industry verticals- most prominent in clinical trials and diagnostic purposes. Among such technology, southern blotting has gained significant traction offering substantial market opportunities for the players across value chain. The technique was first introduced in 1970’s to detect presence of DNA fragment in samples. The technique not only helps in molecular R&D but also to detect some of the most chronic diseases – cancers and genetic diseases – prevalent across world.

Drug discovery advancement along with demand for effective therapeutic treatment for genetic diseases is expected to bolster the southern blotting market worldwide

Over the last few years, many rare diseases surfaced globally. Moreover, rare genetic diseases are on rise owing to changing lifestyle and environmental concerns. As per the estimates, there are over seven thousand rare genetic diseases prevalent globally with over 11% of U.S. population living with these diseases. Over 80% of these diseases are genetic in nature. As a result, pharmaceutical companies are spending heavily on R&D to develop effective drugs. Increased R&D spending coupled with increasing diagnostic cases is expected to create substantial opportunity for players engaged in southern blotting industry.

Forensic science is also expected to increase the overall sales of market to some extent.

Though the market is expected to create substantial opportunity over the forecast period, players might find difficulty in capitalizing emerging regions wherein lower government funding along with high product pricing is a major cause of concerns for the players.

Market Taxonomy:

Coherent Market Insights has segmented the southern blotting market by

• Product
• Application
• End-user

On the basis of product, instruments are expected to be the attractive segment driving huge revenue for market players.   

By application, scientific research holds key market share of overall industry. However, is expected to lose considerable market to medical diagnosis.

North America to dominate the southern blotting market owing to increased government funding and availability of technologies in the region

The southern blotting market report covers market analysis across regions – North America, Europe, Asia Pacific, Latin America, Middle East and Africa.

Global southern blotting market is witnessing a positive trend with North America and Europe as the main engine of growth. North America and Europe are expected to capture a major chunk of the market before easing out to Asia Pacific market by 2021.

North America currently represents the largest regional market for southern blotting industry followed by Europe. Rise in genetic disorders, HIV prevalence, and on-going clinical research across various therapeutic application are some major factors driving the growth in the region. North America is expected to be primarily driven by U.S. – accounting for over 87% of the regional market in 2015.

Penetration rate of southern blotting instruments and consumables in Asia Pacific is low compared to developed regions. However, is expected to witness huge growth over the time frame. China and India are two major power engines of Asia Pacific.

Companies such as BioRad Laboratories and ThermoFisher Scientific spends heavily on molecular diagnostic R&D

Some of the key players in the southern blotting market include BioRad Laboratories, Agilent Technologies, ThermoFisher Scientific, Perkin Elmer Inc., Aplegan, Applied Bio systems, Cleaver Scinetific Ltd, Pall Life Science Laboratories.

Key Developments

Key companies are focused on various business strategies such as merger and acquisition to gain competitive edge in the market. For instance, in March 2018, Thermo Fisher Scientific, a biotechnology product development company, acquired IntegenX, a DNA testing firm for an undisclosed amount.